Nabriva Therapeutics PLC reports results for the quarter ended in March - Earnings Summary

Nabriva Therapeutics

06/05/2021 23:25

* Nabriva Therapeutics PLC  NBRV.OQ  reported a quarterly
adjusted loss of 53 cents​​ per share for the quarter ended
in March. The mean expectation of two analysts for the quarter
was for a loss of 67 cents per share.
* Revenue rose 220.5% to $2.53 million from a year ago​; 
analysts expected $2.25 million.
* Nabriva Therapeutics PLC's reported EPS for the quarter was a
loss of 53 cents​.
* The mean earnings estimate of analysts had risen by about 4.3%
in the last three months.​ 
* In the last 30 days one analyst negatively revised an earnings
estimate and  
* Nabriva Therapeutics PLC shares had fallen by 3.6% this
quarter and lost 33.9% so far this year.
* The company reported a quarterly loss of $13.98 million.
* Wall Street's median 12-month price target for Nabriva
Therapeutics PLC is $6.00 
* The current average analyst rating on the shares is "hold" and
the breakdown of recommendations is 1 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 
This summary was machine generated May 6 at 10:25 p.m. GMT. ​All
figures in US Dollars.​